ES2655614T3 - Composiciones nanoestructuradas de aprepitant, procedimiento para su preparación y composiciones farmacéuticas que las contienen - Google Patents

Composiciones nanoestructuradas de aprepitant, procedimiento para su preparación y composiciones farmacéuticas que las contienen Download PDF

Info

Publication number
ES2655614T3
ES2655614T3 ES11736150.1T ES11736150T ES2655614T3 ES 2655614 T3 ES2655614 T3 ES 2655614T3 ES 11736150 T ES11736150 T ES 11736150T ES 2655614 T3 ES2655614 T3 ES 2655614T3
Authority
ES
Spain
Prior art keywords
aprepitant
unit
procedure
preparation
nanostructured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11736150.1T
Other languages
English (en)
Inventor
Genovéva FILIPCSEI
Zsolt ÖTVÖS
Gábor HELTOVICS
Ferenc Darvas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanoform Cardiovascular Therapeutics Ltd
Original Assignee
Nanoform Cardiovascular Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanoform Cardiovascular Therapeutics Ltd filed Critical Nanoform Cardiovascular Therapeutics Ltd
Application granted granted Critical
Publication of ES2655614T3 publication Critical patent/ES2655614T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición nanoestructurada de aprepitant que comprende aprepitant, dodecilsulfato de sodio y Soluplus, que se obtiene por las siguientes etapas en un reactor de flujo continuo basado en microfluidos: a) se disuelven en etanol aprepitant, dodecilsulfato de sodio y Soluplus; b) la solución de la etapa a) se pasa a la unidad del reactor utilizando una unidad de alimentación; c) mientras tanto, utilizando una segunda unidad de alimentación, se pasa agua destilada a la unidad de mezclado, donde el agua destilada se mezcla con la solución que contiene el aprepitant procedente de la primera unidad del reactor, en donde el caudal de la primera unidad de alimentación es de 3,0 mL/min y el caudal de la segunda unidad de alimentación es de 40,0 mL/min;

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES11736150.1T 2010-06-18 2011-06-17 Composiciones nanoestructuradas de aprepitant, procedimiento para su preparación y composiciones farmacéuticas que las contienen Active ES2655614T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1000325 2010-06-18
HU1000325A HUP1000325A2 (en) 2010-06-18 2010-06-18 Nanostructured aprepitant compositions and process for their preparation
PCT/HU2011/000057 WO2011158053A1 (en) 2010-06-18 2011-06-17 Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
ES2655614T3 true ES2655614T3 (es) 2018-02-20

Family

ID=89989787

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11736150.1T Active ES2655614T3 (es) 2010-06-18 2011-06-17 Composiciones nanoestructuradas de aprepitant, procedimiento para su preparación y composiciones farmacéuticas que las contienen

Country Status (12)

Country Link
US (1) US9504652B2 (es)
EP (1) EP2582697B1 (es)
JP (1) JP2013528642A (es)
CN (1) CN103097379A (es)
AU (1) AU2011266808B2 (es)
DK (1) DK2582697T3 (es)
ES (1) ES2655614T3 (es)
HU (2) HUP1000325A2 (es)
RU (1) RU2595841C2 (es)
SG (1) SG186377A1 (es)
UA (1) UA113390C2 (es)
WO (1) WO2011158053A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619312A (zh) * 2012-05-24 2015-05-13 因诺制药有限公司 阿瑞匹坦注射制剂
EP2866797B1 (en) * 2012-07-06 2020-04-29 Pharmathen S.A. Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof
CN103251556B (zh) * 2013-05-30 2015-04-29 浙江圣兆药物科技股份有限公司 一种阿瑞吡坦纳米混悬剂及其制备方法
DE102013009679A1 (de) 2013-06-11 2014-12-11 Huhtamaki Films Germany Gmbh & Co. Kg Prepregs
ES2750246T3 (es) 2013-10-08 2020-03-25 Innopharma Inc Formulaciones liquidas orales de aprepitant
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP2893919B1 (en) * 2014-01-09 2017-07-12 Sanofi Formulation of aprepitant with enhanced solubility
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
KR102424837B1 (ko) 2014-09-19 2022-07-25 헤론 테라퓨틱스 인코포레이티드 아프레피탄트의 에멀젼 제형
HUP1500055A1 (hu) * 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
JP7026609B2 (ja) 2016-03-10 2022-02-28 大日本住友製薬株式会社 微細粒子含有組成物およびその製法
GR1009002B (el) * 2016-03-22 2017-03-31 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν αντιεμετικο παραγοντα και μεθοδος για την παρασκευη αυτου
GR1009209B (el) * 2016-11-17 2018-02-05 Φαρματεν Αβεε Φαρμακευτικο σκευασμα περιεχον εναν αντιεμετικο παραγοντα και μεθοδος για την παρασκευη αυτου
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
CN110787125B (zh) * 2018-08-02 2021-07-13 北京化工大学 一种阿瑞匹坦纳米制剂及其制备方法
WO2020121006A2 (en) * 2018-10-19 2020-06-18 Innostudio Inc. Method and apparatus to produce nanoparticles in an ostwald ripening flow device with tubes of variable path length
CN116077462A (zh) * 2022-12-01 2023-05-09 北京诺康达医药科技股份有限公司 阿瑞匹坦微丸及其制备方法和包含它的制剂
CN116283947A (zh) * 2023-02-07 2023-06-23 成都医学院 一种阿瑞匹坦共晶及其制备方法和用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
ZA985765B (en) 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
UA76810C2 (uk) 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
AR039625A1 (es) * 2002-04-18 2005-03-02 Merck & Co Inc Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona
WO2005084639A2 (en) * 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
CA2617211A1 (en) 2005-07-29 2007-02-08 Dr. Reddy's Laboratories Ltd. Amorphous aprepitant coprecipitates
CA2622200A1 (en) 2005-09-13 2007-03-22 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
US9227958B2 (en) 2006-02-03 2016-01-05 Glenmark Pharmaceuticals Limited Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
US8217039B2 (en) 2006-03-29 2012-07-10 Dr. Reddy's Laboratories Ltd. Aprepitant polymorph mixtures
US20090209541A1 (en) 2006-06-16 2009-08-20 Dr. Reddy's Laboratories Ltd. Aprepitant compositions
WO2008044102A1 (en) 2006-10-13 2008-04-17 Glenmark Pharmaceuticals Limited Polymorph form of aprepitant and process for the preparation thereof
US20110015191A1 (en) 2007-02-27 2011-01-20 Sandoz Ag Organic compounds
WO2009001203A2 (en) 2007-06-27 2008-12-31 Orchid Chemicals & Pharmaceuticals Limited An improved process for the preparation of aprepitant
EP2254555A4 (en) 2008-02-27 2013-10-09 Reddys Lab Ltd Dr APREPITANT FORMS WITH INCREASED SOLUBILITY AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
WO2009131930A1 (en) * 2008-04-23 2009-10-29 Merck & Co., Inc. Nanoparticle formation via rapid precipitation
HU230862B1 (hu) * 2008-04-28 2018-10-29 DARHOLDING Vagyonkezelő Kft Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
WO2010092591A2 (en) * 2008-06-30 2010-08-19 Usv Limited Novel crystalline polymorphs of 5-[[(2r,3s)-2-[(1r)-1-[3,5- bis(trifluoromethyl) phenyl] ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2- dihydro-3h-1,2,4-triazol-3-one and process for preparation thereof
WO2010140132A1 (en) * 2009-06-02 2010-12-09 Ranbaxy Laboratories Limited Process for the preparation of crystalline aprepitant having form i content
AU2010261509A1 (en) 2009-06-19 2012-02-09 Nanoform Hungary Ltd. Nanoparticulate telmisartan compositions and process for the preparation thereof
HUP0900376A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
HUP0900384A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
AU2010261510A1 (en) 2009-06-19 2012-02-09 Nanoform Hungary Ltd. Nanostructured Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
HUP1000327A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Composition containing nanostructured ezetibime and process for it's preparation

Also Published As

Publication number Publication date
RU2013102030A (ru) 2014-07-27
AU2011266808B2 (en) 2016-02-04
HU1000325D0 (en) 2010-08-30
SG186377A1 (en) 2013-01-30
JP2013528642A (ja) 2013-07-11
UA113390C2 (xx) 2017-01-25
WO2011158053A1 (en) 2011-12-22
RU2595841C2 (ru) 2016-08-27
CN103097379A (zh) 2013-05-08
AU2011266808A1 (en) 2013-02-07
DK2582697T3 (en) 2018-01-15
US9504652B2 (en) 2016-11-29
HUP1000325A2 (en) 2012-01-30
US20130209521A1 (en) 2013-08-15
EP2582697B1 (en) 2017-09-27
HUE037747T2 (hu) 2018-09-28
EP2582697A1 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
ES2655614T3 (es) Composiciones nanoestructuradas de aprepitant, procedimiento para su preparación y composiciones farmacéuticas que las contienen
ES2563323T3 (es) Procedimiento para la preparación de un sólido cristalino a partir de derivados de ácido glicin-N,N-diacético
ES2493965T3 (es) Champú anticaspa
CL2008001194A1 (es) Composicion farmaceutica que comprende florfenico, una ciclodextrina y agua, un solvente y7o una mezcka de los mismos, con al menos 5% de solvente; kit que la contiene; complejo de florfenicol, util para tratr enfermedades respiratorias en animales
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
CL2012002319A1 (es) Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras.
CR20150629A (es) Compuestos químicos
CL2012003009A1 (es) Acido3-(((3-butil-3-etil-(metiloxi)-1-1-dioxido-5-fenil-2,3,4,5-tetrahidro-1,4benxotiazepin-8-il)-metil)-amino)-pentanodioco; composicion farmaceutica que lo comprende; y su uso en un tastorno metabolico. pct.
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
ES2527639T3 (es) Composición de limpieza antimicrobiana con bajo contenido de alcohol
ES2574417T3 (es) Composición de gel
ES2532451T3 (es) Composición herbicida
TW200736208A (en) Isomerisation of pharmaceutical intermediates
PE20130728A1 (es) Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina
PE20151051A1 (es) Formulaciones de liberacion modificada para oprozomib
AR080242A1 (es) Composiciones veterinarias. usos.
ES2616017T3 (es) Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación
AR068817A1 (es) Cocristales y composiciones farmaceuticas que los componen
AR078366A1 (es) Composicion detergente que comprende una mezcla de quelantes
CR20190379A (es) Moduladores del receptor de estrógeno
AR096338A1 (es) (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles
ES2596245T3 (es) Procedimiento para la purificación de acetato de abiraterona
SV2010003701A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre